No one could have predicted 2020’s market action at the beginning of last year. In hindsight it was obvious, but hindsight is 2020. And just as some seemingly obvious market moves are impossible to predict, others are hidden in plain sight…
If you are already a subscriber, click the login button below to get access. Not yet a subscriber? Checkout our publication below and get access today!
As I mentioned yesterday, SRAC didn’t get the votes it needed to extend its merger timeline with Momentus. So if you haven’t put in your vote yet, you need to do that ASAP. Your profits depend on it.
Just wanted to drop you a quick note today — I’ll save the full-blown update for Thursday… But I just had to let you know that your catalysts are crushing it this week!
Today, I provide a quick update following Tuesday’s action-packed Apple event. As much as the media love to dissect events like this, I think they missed some important takeaways…
While we don’t have a crystal ball — nobody does — we do have the next-best thing. One of my colleagues just finished compiling data on what happens after tech pullbacks. In particular, what happens when the Nasdaq Composite pulls back 10% from all-time highs, like it did heading into this week. The results are pretty remarkable...
Last week, we added a new biotech name to the portfolio. Today, I want to share an exciting update on your other clinical-stage biotech play.
Right now, we’re sitting tight, waiting for the merger deal for our portfolio pick. Before I get into the details, here’s the bottom line: Everything looks on track so far.